{"id":"W2567395185","doi":"10.1200/jco.2016.69.9538","title":"Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":219,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Takeda Oncology; Genentech; National Cancer Institute; Onyx Pharmaceuticals; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ovarian cancer; Internal medicine; Fallopian tube; Adverse effect; Gastroenterology; Fallopian tube cancer; Response Evaluation Criteria in Solid Tumors; Population; Nausea; Phases of clinical research; Folate receptor; Oncology; Cancer; Surgery; Chemotherapy; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004171892,0.0003009526,0.003018581,0.000165376,0.0001982842,0.00003699555,0.0002370891,0.0003017756,0.000175608],"category_scores_gemma":[0.00193154,0.000204519,0.0002995205,0.0001236598,0.0003353942,0.0003250162,0.0001608313,0.000994596,0.000001350812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004242413,"about_ca_system_score_gemma":0.002627015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001402144,"about_ca_topic_score_gemma":0.002048605,"domain_scores_codex":[0.9950939,0.0006696691,0.002914726,0.0004606125,0.0004970978,0.000364023],"domain_scores_gemma":[0.993843,0.001505458,0.00336889,0.0004209319,0.0004347438,0.0004269473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1619702,0.02779623,0.4842695,0.0002667749,0.001731892,0.004306798,0.001245778,0.000009855173,0.01701604,0.00002953638,0.000840929,0.3005165],"study_design_scores_gemma":[0.07905639,0.03478615,0.8753377,0.0008980281,0.0007788044,0.0001064436,0.0003261355,0.0001987863,0.0005817953,0.00002559555,0.00769026,0.0002139401],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883147,0.0009521262,0.00003520773,0.008361102,0.001042602,0.0008519468,0.00007486308,0.000008485305,0.000358941],"genre_scores_gemma":[0.9914691,0.004810836,0.002539938,0.000326804,0.0006725379,0.00001369471,0.000008247813,0.00003172661,0.0001270583],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3910682,"threshold_uncertainty_score":0.8340044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08803792109366386,"score_gpt":0.4750723308384164,"score_spread":0.3870344097447526,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}